Why the study?
Patients with advanced ischemic cardiomyopathy and left ventricular dysfunction face complex treatment decisions and may not receive appropriate therapy due to perceived risk, leading to suboptimal outcomes.
This review outlines a programmatic approach to managing advanced ischemic cardiomyopathy, emphasizing the integration of microaxial support and tailored therapeutic decision-making.
Optimal management of advanced ischemic cardiomyopathy remains challenging; review leaves open individualized pathway selection.
Patients with advanced ischemic cardiomyopathy manifesting as left ventricular dysfunction exist along a spectrum of severity and risk, and thus decision-making surrounding optimal management is challenging. Treatment pathways can include medical therapy as well as revascularization through percutaneous coronary intervention or coronary artery bypass grafting. Additionally, temporary and durable mechanical circulatory support, as well as heart transplantation, may be optimal for select patients. Given this spectrum of risk and the complexity of treatment pathways, patients may not receive appropriate therapy given their perceived risk, which can lead to sub-satisfactory outcomes. In this review, we discuss the identification of high-risk ischemic cardiomyopathy patients, along with our programmatic approach to patient evaluation and perioperative optimization. We also discuss our strategies for therapeutic decision-making designed to optimize both short- and long-term patient outcomes.
No takes yet. Share an insight, caveat, or question.
Maigrot et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: